Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma.

Soetekouw PM, Koopman M, Burger D, Tjan-Heijnen VC, De Mulder PH.

Acta Oncol. 2009;48(1):154-6. doi: 10.1080/02841860802047403. No abstract available.

PMID:
19101828
2.

Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation.

van Herpen CM, van der Voort R, van der Laak JA, Klasen IS, de Graaf AO, van Kempen LC, de Vries IJ, Boer TD, Dolstra H, Torensma R, van Krieken JH, Adema GJ, De Mulder PH.

Int J Cancer. 2008 Nov 15;123(10):2354-61. doi: 10.1002/ijc.23756.

3.

Aberrant expression of the hematopoietic-restricted minor histocompatibility antigen LRH-1 on solid tumors results in efficient cytotoxic T cell-mediated lysis.

Overes IM, Levenga TH, Vos JC, van Horssen-Zoetbrood A, van der Voort R, De Mulder PH, de Witte TM, Dolstra H.

Cancer Immunol Immunother. 2009 Mar;58(3):429-39. doi: 10.1007/s00262-008-0569-3. Epub 2008 Aug 22.

PMID:
18719914
4.

Possibilities for transborder cooperation in breast cancer care in Europe: a comparative analysis regarding the content, quality and evidence use of breast cancer guidelines.

Wennekes L, Hermens RP, van Heumen K, Runde V, Schoelen H, Wollersheim HC, Grol RP, de Mulder PH, Ottevanger PB.

Breast. 2008 Oct;17(5):464-71. doi: 10.1016/j.breast.2008.01.008. Epub 2008 May 1.

5.

[Guideline 'Renal cell carcinoma'].

Mulders PF, Brouwers AH, Hulsbergen-van der Kaa CA, van Lin EN, Osanto S, de Mulder PH.

Ned Tijdschr Geneeskd. 2008 Feb 16;152(7):376-80. Review. Dutch.

PMID:
18380384
6.

[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].

de Mulder PH, Haanen JB, Sleijfer S, Kruit WH, Gietema JA, Richel DJ, Groenewegen G, Voest EE, van den Eertwegh AJ, Osanto S, Jansen RL, Mulders PF.

Ned Tijdschr Geneeskd. 2008 Feb 16;152(7):371-5. Review. Dutch.

PMID:
18380383
7.

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, del Muro XG, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Galvis OL, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Ares LP, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H.

Eur Urol. 2008 Mar;53(3):478-96. doi: 10.1016/j.eururo.2007.12.024. Epub 2007 Dec 26. Review.

PMID:
18191324
8.

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, del Muro XG, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Galvis OL, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz-Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H.

Eur Urol. 2008 Mar;53(3):497-513. doi: 10.1016/j.eururo.2007.12.025. Epub 2007 Dec 26.

PMID:
18191015
9.

Targeted therapy in metastatic renal cell carcinoma.

De Mulder PH.

Ann Oncol. 2007 Jul;18 Suppl 9:ix98-102. Review. No abstract available.

PMID:
17631605
10.

Renal cancer.

Corgna E, Betti M, Gatta G, Roila F, De Mulder PH.

Crit Rev Oncol Hematol. 2007 Dec;64(3):247-62. Epub 2007 Jul 26. Review.

PMID:
17662611
11.

Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion.

Levenga H, Woestenenk R, Schattenberg AV, Maas F, Jansen JH, Raymakers R, De Mulder PH, van de Wiel-van Kemenade E, Schaap N, de Witte T, Dolstra H.

Bone Marrow Transplant. 2007 Sep;40(6):585-92. Epub 2007 Jul 16.

PMID:
17637687
12.

Re: p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy.

Span PN, de Mulder PH, Sweep FC.

J Natl Cancer Inst. 2007 May 2;99(9):738. No abstract available.

PMID:
17470742
13.

Do the results of the new trials change the standard treatment of metastatic renal cell cancer?

Mulder SF, van Spronsen DJ, De Mulder PH.

Onkologie. 2007 May;30(5):260-4. Epub 2007 Apr 25.

PMID:
17460422
14.

Carbonic anhydrase IX expression is more predictive than prognostic in breast cancer.

Span PN, Bussink J, De Mulder PH, Sweep FC.

Br J Cancer. 2007 Apr 23;96(8):1309; author reply 1310. Epub 2007 Mar 27. No abstract available.

15.

Targeted approaches for treating advanced clear cell renal carcinoma.

van Spronsen DJ, De Mulder PH.

Onkologie. 2006 Sep;29(8-9):394-402. Epub 2006 Sep 6. Review.

PMID:
16974118
16.

The role of adjuvant therapy in non-metastatic RCC.

Bleumer I, de Mulder PH, Mulders PF.

Can J Urol. 2006 Apr;13 Suppl 2:57-62. Review.

PMID:
16672131
17.

Acute arterial occlusion after chemotherapy for testicular cancer.

Lesterhuis WJ, van Spronsen DJ, Schultze-Kool LJ, de Mulder PH.

Lancet Oncol. 2005 Nov;6(11):910. No abstract available.

PMID:
16257801
18.

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).

Fosså SD, Paluchowska B, Horwich A, Kaiser G, de Mulder PH, Koriakine O, van Oosterom AT, de Prijck L, Collette L, de Wit R; EORTC GU Group.

Br J Cancer. 2005 Nov 28;93(11):1209-14.

19.

Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response.

Brouwers AH, Buijs WC, Mulders PF, de Mulder PH, van den Broek WJ, Mala C, Oosterwijk E, Boerman OC, Corstens FH, Oyen WJ.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7178s-7186s.

20.

Timely withdrawal of G-CSF reduces the occurrence of thrombocytopenia during dose-dense chemotherapy.

Timmer-Bonte JN, de Mulder PH, Peer PG, Beex LV, Tjan-Heijnen VC.

Breast Cancer Res Treat. 2005 Sep;93(2):117-23.

PMID:
16187231
21.

Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.

Brouwers AH, Mulders PF, de Mulder PH, van den Broek WJ, Buijs WC, Mala C, Joosten FB, Oosterwijk E, Boerman OC, Corstens FH, Oyen WJ.

J Clin Oncol. 2005 Sep 20;23(27):6540-8.

PMID:
16170161
22.

Leptomeningeal carcinomatosis in relapsed non-seminoma testis: a 1-year complete remission with high-dose chemotherapy.

Denissen NH, van Spronsen DJ, Smilde TJ, De Mulder PH.

Anticancer Drugs. 2005 Sep;16(8):897-9.

PMID:
16096440
23.

Novel treatment strategies in clear-cell metastatic renal cell carcinoma.

van Spronsen DJ, de Weijer KJ, Mulders PF, De Mulder PH.

Anticancer Drugs. 2005 Aug;16(7):709-17. Review.

PMID:
16027518
24.

Novel treatments for metastatic renal cell carcinoma.

van Spronsen DJ, Mulders PF, De Mulder PH.

Crit Rev Oncol Hematol. 2005 Sep;55(3):177-91. Review.

PMID:
15979888
25.
26.

The quality of chemotherapy and its quality assurance.

Ottevanger PB, De Mulder PH.

Eur J Surg Oncol. 2005 Aug;31(6):656-66. Review.

PMID:
15893906
27.

Interleukin-12 has no effect on vascular density, perfusion, hypoxia and proliferation of an implanted human squamous cell carcinoma xenograft tumour despite up-regulation of ICAM-1.

van Herpen CM, Bussink J, van der Kogel AJ, Peeters WJ, van der Voort R, van Schijndel A, de Wilde PC, Adema GJ, de Mulder PH.

Anticancer Res. 2005 Mar-Apr;25(2A):1015-21.

28.

Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.

van Herpen CM, van der Laak JA, de Vries IJ, van Krieken JH, de Wilde PC, Balvers MG, Adema GJ, De Mulder PH.

Clin Cancer Res. 2005 Mar 1;11(5):1899-909.

29.

[A young man with rapidly progressing dyspnoea and a mediastinal mass].

van Spronsen DJ, van den Berkmortel FW, Bootsma GP, de Mulder PH.

Ned Tijdschr Geneeskd. 2004 Nov 13;148(46):2286-9. Dutch.

PMID:
15586435
30.

Current treatment of renal cell carcinoma.

De Mulder PH, van Herpen CM, Mulders PA.

Ann Oncol. 2004;15 Suppl 4:iv319-28. Review. No abstract available.

PMID:
15477330
31.

European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).

Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, von der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C; European Germ Cell Cancer Consensus Group.

Ann Oncol. 2004 Sep;15(9):1377-99. Review.

PMID:
15319245
32.

Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma.

Fosså SD, Mickisch GH, De Mulder PH, Horenblas S, van Oosterom AT, van Poppel H, Fey M, Croles JJ, de Prijck L, Van Glabbeke M.

Cancer. 2004 Aug 1;101(3):533-40.

33.

[The Dutch Health Council report on palliative chemotherapy: possible confusion on ideas].

Verweij J, de Mulder PH, Pinedo HM.

Ned Tijdschr Geneeskd. 2004 Apr 3;148(14):651-4. Dutch.

PMID:
15106314
34.

Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes.

van Herpen CM, Looman M, Zonneveld M, Scharenborg N, de Wilde PC, van de Locht L, Merkx MA, Adema GJ, de Mulder PH.

Clin Cancer Res. 2004 Apr 15;10(8):2626-35.

35.

[Paraneoplastic syndromes in three patients with renal cell carcinoma].

Steffens MG, de Mulder PH, Mulders PF.

Ned Tijdschr Geneeskd. 2004 Mar 6;148(10):487-92. Dutch.

PMID:
15042897
36.

Adherence to the guidelines of the CCCE in the treatment of node-positive breast cancer patients.

Ottevanger PB, De Mulder PH, Grol RP, van Lier H, Beex LV.

Eur J Cancer. 2004 Jan;40(2):198-204.

PMID:
14728933
37.

Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.

Brouwers AH, Buijs WC, Oosterwijk E, Boerman OC, Mala C, De Mulder PH, Corstens FH, Mulders PF, Oyen WJ.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3953S-60S.

38.
39.

[Surgical treatment of tumor metastases in the lungs, brain or liver].

van den Berkmortel FW, Ruers TJ, Bootsma GP, Verhagen AF, de Mulder PH.

Ned Tijdschr Geneeskd. 2003 May 10;147(19):904-8. Review. Dutch.

PMID:
12768804
40.

Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20).

Fosså SD, de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Cook P, de Prijck L, Stenning S, Aaronson NK, Bottomley A, Collette L; European Organization for Research and Treatment of Cancer Genitourinary Group 30941; Medical Research Council Testicular Cancer Study Group TE20.

J Clin Oncol. 2003 Mar 15;21(6):1107-18.

PMID:
12637478
41.

Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.

Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, Debruyne FM, de Mulder PH, Oosterwijk E, Mulders PF.

J Immunother. 2002 Nov-Dec;25(6):500-8.

PMID:
12439347
42.

Treatment options in hormone resistant prostate cancer.

De Mulder PH, Schalken JA, Sternberg CN.

Ann Oncol. 2002;13 Suppl 4:95-102. Review. No abstract available.

PMID:
12401673
43.

The role of adjuvant immunotherapy in renal cell carcinoma.

Mulders PF, De Mulder PH.

Curr Urol Rep. 2002 Feb;3(1):44-9. Review.

PMID:
12084219
44.

Effects of quality of treatment on prognosis in primary breast cancer patients treated in daily practice.

Ottevanger PB, De Mulder PH, Grol RP, Van Lier H, Beex LV.

Anticancer Res. 2002 Jan-Feb;22(1A):459-65.

PMID:
12017333
45.

Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.

de Jonge MJ, Punt CJ, Sparreboom A, Planting AS, Peters ME, van De Schraaf J, Jackman A, Smith R, de Mulder PH, Verweij J.

J Clin Oncol. 2002 Apr 1;20(7):1923-31.

PMID:
11919253
46.

Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma.

van Herpen CM, De Mulder PH.

Crit Rev Oncol Hematol. 2002 Mar;41(3):327-34. Review.

PMID:
11880208
47.
48.

From chemoprevention and organ preservation programmes to postoperative management: major achievements and strategies of the EORTC Head and Neck Cancer Group.

Bernier J, Vermorken JB, Debruyne C, Andry G, Licitra L, Grandi C, Langendijk H, De Mulder PH, Lefèbvre JL.

Eur J Cancer. 2002 Mar;38 Suppl 4:S75-81.

PMID:
11858970
49.

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.

Sternberg CN, de Mulder PH, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, Witjes F, Spina M, van Groeningen CJ, de Balincourt C, Collette L; European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.

J Clin Oncol. 2001 May 15;19(10):2638-46.

PMID:
11352955

Supplemental Content

Loading ...
Support Center